The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

A 'frontal variant of Alzheimer's disease' has been described in patients with predominant behavioural or dysexecutive deficits caused by Alzheimer's disease pathology. The description of this rare Alzheimer's disease phenotype has been limited to case reports and small series, and many clinical, neuroimaging and neuropathological characteristics are not well understood. In this retrospective study, we included 55 patients with Alzheimer's disease with a behavioural-predominant presentation (behavioural Alzheimer's disease) and a neuropathological diagnosis of high-likelihood Alzheimer's disease (n = 17) and/or biomarker evidence of Alzheimer's disease pathology (n = 44). In addition, we included 29 patients with autopsy/biomarker-defined Alzheimer's disease with a dysexecutive-predominant syndrome (dysexecutive Alzheimer's disease). We performed structured chart reviews to ascertain clinical features. First symptoms were more often cognitive (behavioural Alzheimer's disease: 53%; dysexecutive Alzheimer's disease: 83%) than behavioural (behavioural Alzheimer's disease: 25%; dysexecutive Alzheimer's disease: 3%). Apathy was the most common behavioural feature, while hyperorality and perseverative/compulsive behaviours were less prevalent. Fifty-two per cent of patients with behavioural Alzheimer's disease met diagnostic criteria for possible behavioural-variant frontotemporal dementia. Overlap between behavioural and dysexecutive Alzheimer's disease was modest (9/75 patients). Sixty per cent of patients with behavioural Alzheimer's disease and 40% of those with the dysexecutive syndrome carried at least one APOE ε4 allele. We also compared neuropsychological test performance and brain atrophy (applying voxel-based morphometry) with matched autopsy/biomarker-defined typical (amnestic-predominant) Alzheimer's disease (typical Alzheimer's disease, n = 58), autopsy-confirmed/Alzheimer's disease biomarker-negative behavioural variant frontotemporal dementia (n = 59), and controls (n = 61). Patients with behavioural Alzheimer's disease showed worse memory scores than behavioural variant frontotemporal dementia and did not differ from typical Alzheimer's disease, while executive function composite scores were lower compared to behavioural variant frontotemporal dementia and typical Alzheimer's disease. Voxel-wise contrasts between behavioural and dysexecutive Alzheimer's disease patients and controls revealed marked atrophy in bilateral temporoparietal regions and only limited atrophy in the frontal cortex. In direct comparison with behavioural and those with dysexecutive Alzheimer's disease, patients with behavioural variant frontotemporal dementia showed more frontal atrophy and less posterior involvement, whereas patients with typical Alzheimer's disease were slightly more affected posteriorly and showed less frontal atrophy (P < 0.001 uncorrected). Among 24 autopsied behavioural Alzheimer's disease/dysexecutive Alzheimer's disease patients, only two had primary co-morbid FTD-spectrum pathology (progressive supranuclear palsy). In conclusion, behavioural Alzheimer's disease presentations are characterized by a milder and more restricted behavioural profile than in behavioural variant frontotemporal dementia, co-occurrence of memory dysfunction and high APOE ε4 prevalence. Dysexecutive Alzheimer's disease presented as a primarily cognitive phenotype with minimal behavioural abnormalities and intermediate APOE ε4 prevalence. Both behavioural Alzheimer's disease and dysexecutive Alzheimer's disease presentations are distinguished by temporoparietal-predominant atrophy. Based on the relative sparing of frontal grey matter, we propose to redefine these clinical syndromes as 'the behavioural/dysexecutive variant of Alzheimer's disease' rather than frontal variant Alzheimer's disease. Further work is needed to determine whether behavioural and dysexecutive-predominant presentations of Alzheimer's disease represent distinct phenotypes or a single continuum.

[1]  D. Michaelson.  APOE4: The most prevalent yet understudied risk factor for Alzheimer’s disease , 2016, Neurobiology of Aging.

[2]  K. Blennow,et al.  The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? , 2014, Alzheimer's & Dementia.

[3]  D. Michaelson.  APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[4]  Emily N. Manning,et al.  APOE epsilon 4 Is Associated with Disproportionate Progressive Hippocampal Atrophy in AD (vol 9, e97608, 2014) , 2014 .

[5]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[6]  Nick C Fox,et al.  APOE ε4 Is Associated with Disproportionate Progressive Hippocampal Atrophy in AD , 2014, PloS one.

[7]  C. Jack,et al.  TDP-43 is a key player in the clinical features associated with Alzheimer’s disease , 2014, Acta Neuropathologica.

[8]  Carmen Guerrero Márquez,et al.  Variante frontal de la enfermedad de Alzheimer. Dos casos confirmados anatomopatológicamente y revisión de la bibliografía , 2013 .

[9]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[10]  V. Burt,et al.  Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. , 2013, NCHS data brief.

[11]  Cindee M. Madison,et al.  Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  P. Scheltens,et al.  Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease , 2013, Neurobiology of Aging.

[13]  A. Brickman,et al.  Dysexecutive Versus Amnestic Alzheimer Disease Subgroups: Analysis of Demographic, Genetic, and Vascular Factors , 2013, Alzheimer disease and associated disorders.

[14]  P. Scheltens,et al.  Impact of molecular imaging on the diagnostic process in a memory clinic , 2013, Alzheimer's & Dementia.

[15]  Sue J. Kang,et al.  The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments , 2013, Neurobiology of Aging.

[16]  Cindee M. Madison,et al.  Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[17]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[18]  E. Teng,et al.  Clinicopathologic differences among patients with behavioral variant frontotemporal dementia , 2013, Neurology.

[19]  W. M. van der Flier,et al.  Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia , 2013, Neurology.

[20]  G. Chételat,et al.  Region-Specific Hierarchy between Atrophy, Hypometabolism, and β-Amyloid (Aβ) Load in Alzheimer's Disease Dementia , 2012, The Journal of Neuroscience.

[21]  M. Mendez,et al.  Nonamnestic Presentations of Early-Onset Alzheimer’s Disease , 2012, American journal of Alzheimer's disease and other dementias.

[22]  Frederik Barkhof,et al.  Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. , 2012, Brain : a journal of neurology.

[23]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[24]  Frederik Barkhof,et al.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[26]  W. Jagust,et al.  Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD , 2011, Neurology.

[27]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[28]  J. Trojanowski,et al.  Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.

[29]  J. Molinuevo,et al.  Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease , 2011, Neurology.

[30]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[31]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[32]  Nick C Fox,et al.  Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele , 2011, The Lancet Neurology.

[33]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[34]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[35]  David A Wolk,et al.  Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  David A Wolk,et al.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease , 2010, Proceedings of the National Academy of Sciences.

[37]  E. Larsson,et al.  Alzheimer's disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI). , 2010, Archives of gerontology and geriatrics.

[38]  M. Weiner,et al.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. , 2010, Brain : a journal of neurology.

[39]  D. Chudy,et al.  Frontal Variant of Alzheimer's Disease: Clinico-CSF-Pathological Correlation , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[40]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[41]  Andrew Kertesz,et al.  Differentiating the frontal variant of Alzheimer's disease , 2009, International journal of geriatric psychiatry.

[42]  Adam Gazzaley,et al.  Clinical‐neuroimaging characteristics of dysexecutive mild cognitive impairment , 2009, Annals of neurology.

[43]  A. Venneri,et al.  Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[44]  Frederik Barkhof,et al.  Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. , 2008, Radiology.

[45]  Nancy Johnson,et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.

[46]  A. Monsch,et al.  Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease , 2008, Nature Clinical Practice Neurology.

[47]  B. Peng.  Issues concerning the biological repair of intervertebral disc degeneration , 2008, Nature Clinical Practice Rheumatology.

[48]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[49]  Julie S. Snowden,et al.  Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk , 2007, Cortex.

[50]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[51]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[52]  Andrew Kertesz,et al.  Argyrophilic thorny astrocyte clusters in association with Alzheimer’s disease pathology in possible primary progressive aphasia , 2007, Acta Neuropathologica.

[53]  J. Schneider,et al.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.

[54]  D. Dickson,et al.  TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease , 2007, Annals of neurology.

[55]  A. Larner.  “Frontal variant Alzheimer's disease”: A reappraisal , 2006, Clinical Neurology and Neurosurgery.

[56]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[57]  Jennifer Farmer,et al.  Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.

[58]  J. Attems.  Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms , 2005, Acta Neuropathologica.

[59]  Michael Weiner,et al.  Effects of white matter lesions and lacunes on cortical function. , 2004, Archives of neurology.

[60]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[61]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[62]  R. Mayeux,et al.  A comparison of family history of psychiatric disorders among patients with early- and late-onset Alzheimer's disease. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[63]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[64]  Martin Keller,et al.  The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys , 2003, International journal of methods in psychiatric research.

[65]  K. Boone,et al.  Functional Ability in Executive Variant Alzheimer's Disease and Typical Alzheimer's Disease , 2002, The Clinical neuropsychologist.

[66]  B. Dubois,et al.  Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis , 2002, European Journal of Human Genetics.

[67]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[68]  D. Dickson,et al.  Argyrophilic Grain Disease Is a Sporadic 4‐Repeat Tauopathy , 2002, Journal of neuropathology and experimental neurology.

[69]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[70]  J. Cummings,et al.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[71]  R N Kalaria,et al.  Overlap between pathology of Alzheimer disease and vascular dementia. , 1999, Alzheimer disease and associated disorders.

[72]  C. Cotman,et al.  Clinical and pathological evidence for a frontal variant of Alzheimer disease. , 1999, Archives of neurology.

[73]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[74]  D. Neary,et al.  Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia , 1999, Journal of neurology, neurosurgery, and psychiatry.

[75]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[76]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[77]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[78]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[79]  L. S. Steijns,et al.  [Apolipoprotein E polymorphism and Alzheimer disease]. , 1996, Tijdschrift voor gerontologie en geriatrie.

[80]  E Magni,et al.  Executive dysfunction in early Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[81]  A. Damasio,et al.  The return of Phineas Gage: clues about the brain from the skull of a famous patient. , 1994, Science.

[82]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[83]  R. Levy,et al.  The Lewy-Body Variant of Alzheimer's Disease , 1993, British Journal of Psychiatry.

[84]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[85]  Benson Df,et al.  Posterior cortical atrophy. , 1988, Archives of neurology.

[86]  C. Soldatos,et al.  Nosology and Prevalence of Sleep Disorders , 1987, Seminars in neurology.

[87]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[88]  F. Fremont‐Smith,et al.  The cerebrospinal fluid , 1938 .

[89]  C. Rowe,et al.  Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. , 2015, Journal of Alzheimer's disease : JAD.

[90]  V. Coronado,et al.  Epidemiology of traumatic brain injury. , 2015, Handbook of clinical neurology.

[91]  W. M. van der Flier,et al.  Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. , 2014, Journal of Alzheimer's disease : JAD.

[92]  Frederik Barkhof,et al.  Optimizing patient care and research: the Amsterdam Dementia Cohort. , 2014, Journal of Alzheimer's disease : JAD.

[93]  J. Hodges,et al.  Distribution of pathology in frontal variant Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[94]  J. Porta‐Etessam,et al.  [Frontal variant of Alzheimer's disease. Two pathologically confirmed cases and a literature review]. , 2013, Revista de neurologia.

[95]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[96]  C. Sorg,et al.  Disconnection of frontal and parietal areas contributes to impaired attention in very early Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[97]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[98]  H. Braak,et al.  Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria , 1998, Journal of Neural Transmission.

[99]  J. Harrison,et al.  Posterior cortical atrophy. , 1989, Clinical and experimental neurology.

[100]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.